cigna glp 1 2025 requirements to offer $200 Wegovy, Zepbound weight-loss benefit New Evernorth program to cap

However, since the FDA decided that NMN can no longer be sold as a supplement (link), Momentous stopped selling it

A larger meta-analysis encompassing over 77,000 participants similarly reported a reduced overall risk of respiratory diseases with GLP-1 receptor agonist treatment, but pulmonary fibrosis was not analysed as a discrete outcome, and no fibrotic endpoints were prospectively assessed [64]

[DOI] [PMC free article] [PubMed] [Google Scholar] 121.Sultan R., Ahmed A., Wei L., Saeed H., Islam M., Ishaq M

Primarily, the available research is often characterized by small study populations and short intervention durations, which limit statistical power and the ability to fully understand long-term effects

Biographical Memoirs of Fellows of the Royal Society